Halcinonide

Summary

Halcinonide (CHEMBL1200845) is an approved small molecule (ATC D07AD02); indicated across 1 condition including skin disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D07AD02
• Indications: 1 condition
• Chemistry: 455 Da · C24H32ClFO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200845
Name	Halcinonide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	443943
ATC	D07AD02
Molecular formula	C24H32ClFO5
Molecular weight	455
InChIKey	MUQNGPZZQDCDFT-JNQJZLCISA-N

SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F

IUPAC name: (1S,2S,4R,8S,9S,11S,12R,13S)-8-(2-chloroacetyl)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one

Also known as: Halcinonida, Halcinonide, Halog, Halog-e, NSC-758413, SO 18566, SO-18566, SQ 18566, SQ-18566, SID56463097, HALCINONIDE, halcinonide

Patent coverage: 6,061 distinct patent families (22,539 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Androgen receptor, Beta-lactamase, Glucocorticoid receptor, Progesterone receptor, Androgen receptor.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C1	9.13	Ki	0.73	nM	CHEMBL_ACT_7672819
NR3C1	8.79	IC50	1.61	nM	CHEMBL_ACT_7672818
PGR	8.52	AC50	3	nM	CHEMBL_ACT_25204023
AR	6.77	AC50	168.5	nM	CHEMBL_ACT_25203090
P15207	6.23	Ki	590	nM	CHEMBL_ACT_7674971
P15207	6.05	IC50	885	nM	CHEMBL_ACT_7674970
P00811	5	Potency	10000	nM	CHEMBL_ACT_4689877

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
skin disorder	4	MONDO:0005093	EFO:0000701

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).